Article

Respiratory Outcomes of Interrupted Modulator Therapies in Children with Cystic Fibrosis

2024-08-28

Abstract excerpt

<h4>Background: </h4> Cystic fibrosis (CF) is a multisystemic disease caused by mutations in the cystic fibrosis transmembrane conductance regulator ( CFTR ) gene, resulting in defective synthesis or function of the CFTR protein. Historically, CF treatment focused on managing symptoms and complications. Fortunately, modulator drugs are now available to directly target the defective CFTR protein. However, in some...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 263f3bad-707d-5f9e-b0d8-a353bc6f5ee2
DOI: 10.22541/au.172487729.96061300/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Respiratory Outcomes of Interrupted Modulator Therapies in Children with Cystic FibrosisDOI 10.22541/au.172487729.96061300/v1Read

Impact of chronic medication de-escalation in patients with cystic fibrosis taking elexacaftor, tezacaftor, ivacaftor: A retrospective review.Semantic proximity Read

Real-life initiation of lumacaftor/ivacaftor combination in adults with cystic fibrosis homozygous for the Phe508del CFTR mutation and severe lung disease.Semantic proximity Read

Clinical change 2 years from start of elexacaftor-tezacaftor-ivacaftor in severe cystic fibrosis.Semantic proximity Read

Modulator-refractory cystic fibrosis: Defining the scope and challenges of an emerging at-risk population.Semantic proximity Read

Real world outcomes of CFTR modulator therapy in Australian adults and children.Semantic proximity Read

Real-world data on the efficacy and safety of tezacaftor-ivacaftor in adults living with cystic fibrosis homozygous for F508del and heterozygous for F508del and a residual function mutation.Semantic proximity Read

Update on Clinical Outcomes of Highly Effective Modulator Therapy.Semantic proximity Read

Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D-CFTR mutation treated with ivacaftor.Semantic proximity Read

An Observational Study of Outcomes and Tolerances in Patients with Cystic Fibrosis Initiated on Lumacaftor/Ivacaftor.Semantic proximity Read

Use of CFTR modulators in special populations, part 2: Severe lung disease.Semantic proximity Read

EFFECT OF ELEXACAFTOR/TEZACAFTOR/IVACAFTOR ON ANNUAL RATE OF LUNG FUNCTION DECLINE IN PEOPLE WITH CYSTIC FIBROSIS.Semantic proximity Read

Impact of Elexacaftor/Tezacaftor/Ivacaftor on Systemic Antibiotic Utilization in Pediatric Patients with Cystic FibrosisSemantic proximity Read